Fluad (influenza vaccine (surface antigen, inactivated, adjuvanted))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (surface antigen, inactivated, adjuvanted)
- Company
- Seqirus Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Influenza, Human
- CHMP opinion
- Thu 17 Oct 2024
- EU approval
- Fri 15 Nov 2024
- Application
- EMEA/H/C/006538
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in adults 50 years of age and older. Fluad should be used in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aujemflu Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Flucelvax Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Flucelvax Tetra Withdrawn · Seqirus Netherlands B.V.
- 🇪🇺 Fluad Tetra Withdrawn · Seqirus Netherlands B.V.
- 🇪🇺 Optaflu Expired · Seqirus GmbH
Follow Fluad
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.